Premarket Decliner
SNSE Sensei Biotherapeutics17.58+3.90+28.5%
Premarket:7.25-10.33 (-58.8%)
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Globe NewswireFri, 17-Oct 8:00 AM
